3L Metastatic Pancreatic Cancer (Cohort B)

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for First- and Second-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer